News

Hims & Hers Health has been hit with an FTC complaint and multiple securities class action lawsuits alleging improper sharing of sensitive health data and misleading billing practices, events that have already drawn regulatory scrutiny and legal pressure by mid‑2026. The allegations cut to the core of Hims & Hers’ telehealth model, putting its privacy assurances and subscription-based business practices under a spotlight that could reshape how it operates. Against this backdrop of FTC action...

Hims & Hers Health (NYSE:HIMS) is facing a new consumer class action lawsuit alleging misrepresentation of user privacy and unauthorized sharing of sensitive health data. The lawsuit follows a recent FTC civil enforcement action against the company that raised similar concerns about handling of consumer health information. Plaintiffs claim the company misled users about how their health data would be used and shared, potentially affecting customer trust and future regulatory scrutiny. As...

Andrew Dudum told CNBC the agency wanted "more of a headline than a real agreement" after years of cooperative talks

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

The FTC has filed a lawsuit against Hims & Hers Health alleging improper sharing of sensitive health data with advertising platforms and deceptive billing practices. Hims & Hers Health has publicly rejected the allegations and issued a formal response defending its data and billing practices. This action represents a new phase of regulatory scrutiny for NYSE:HIMS that investors are assessing alongside the company’s broader telehealth business. Hims & Hers Health, traded on the NYSE under...

Two class action lawsuits claim Hims & Hers Health did not adequately safeguard sensitive customer data during recent data breaches. The suits allege delayed notification to affected customers and increased risk of identity theft, and they seek damages plus stronger data security oversight. These cases introduce fresh legal and reputational questions for NYSE:HIMS that have not been widely covered so far. For investors watching NYSE:HIMS, this legal development adds a new angle to a stock...